Home > Name List By h > hydroxyurea

CAS No 127-07-1 , hydroxyurea

  • Name: hydroxyurea
  • Synonyms: Hydrea; Hydura; Droxia; Biosupressin; Oxyurea; N-Hydroxyurea; Litalir; Onco-carbide;Hydroxycarbamide;hydroxyurea;
  • CAS Registry Number:
  • Transport: HAZARD
  • Melting Point: 142-146 ºC
  • Flash Point: °C
  • Boiling Point: °Cat760mmHg
  • Density: 1.457g/cm3
  • Refractive index: 1.543
  • Safety Statements: R46;R61
  • Hazard Symbols: T: Toxic;
  • Flash Point: °C
  • EINECS: 204-821-7
  • Molecular Weight: 76.05466
  • InchiKey: VSNHCAURESNICA-UHFFFAOYSA-N
  • InChI: InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
  • Risk Statements: S45;S53
  • Molecular Formula: CH4N2O2
  • Molecular Structure:CAS No:127-07-1 hydroxyurea
Search by region :

Select to

127-07-1 Hydroxyurea

  • China Shanghai Xunxin Chemical Co., Ltd [Manufacturers]
  • Tel: +86-(21)-38218795
  • Fax: +86-(21)-38218795
  • Address: 580 Lane, Kanghong Road, Pudong New District, Shanghai 201315, Shanghai,ShanghaiChina
Contact Supplier

127-07-1 Hydroxyurea

Contact Supplier

127-07-1 Hydroxycarbamide

Contact Supplier

127-07-1 HYDROXY UREA

  • India JAI RADHE SALES null
  • Fax: 0091-79-26569884
  • Address: 309/310 HARIKRUPA TOWER,NR.OLD SHARDA MANDIR CHAR RASTA,ELLISBRIDGE ,AHMEDABAD,GUJRAT , INDIA. null,nullIndia
Contact Supplier

127-07-1 HYDROXYUREA

  • United States Research Organics, Inc. [Manufacturer]
  • Tel: 216-883-8025/ 800-321-0570
  • Fax: 216-883-1576
  • Address: 4353 East 49th Street
    Cleveland, OH 44125 null,nullUnited States
Contact Supplier

127-07-1 Hydroxyurea

  • China Qingdao Chinaoil Co., Ltd null
  • Fax: +86-532-85713888 85723888
  • Address: 22/F,Golden Light Tower,No.56, Xianggang Zhong Road, Qingdao 266071, China null,nullChina
Contact Supplier

127-07-1 Hydroxyurea

  • India Shreeji Pharma International [Manufacturers]
  • Tel: +91-265-3019110
  • Fax: +91-265-2465036
  • Address: FF/10, Narsinghdham Complex, Sangam Chararasta, Harni Road, Vadodara, Gujarat 390018, Vadodara,GujaratIndia
Contact Supplier

127-07-1 HYDROXYUREA

  • United States ACIC [Manufacturer]
  • Tel: 800-265-6727/ 519-751-3668
  • Fax: 519-751-1378
  • Address: 11772 West Sample Road,
    Coral Springs, Florida, 33065 USA null,nullUnited States
Contact Supplier

127-07-1 Hydroxyurea

  • United States Tecoland Corporation null
  • Tel: +1-(732)-603-9577
  • Fax: +1-(732)-906-1522
  • Address: 100 Menlo Park Drive, Suite 316, Edison, New Jersey 08837-2428, null,nullUnited States
Contact Supplier

127-07-1 Hydroxycarbamide

  • China Facus Pharmaceutical Co., Ltd. [Manufacturers]
  • Tel: +86-(574)-6237-8411
  • Fax: +86-(574)-6237-8410
  • Address: 24Fl, Yuanjing Building, Beilun, Ningbo, Zhejiang 315800, Ningbo,ZhejiangChina
Contact Supplier

Select to

References of hydroxyurea
Title: Hydroxyurea
CAS Registry Number: 127-07-1
Synonyms: Hydroxycarbamide
Trademarks: Droxia (BMS); Hydrea (BMS); Litalir (BMS)
Molecular Formula: CH4N2O2
Molecular Weight: 76.05
Percent Composition: C 15.79%, H 5.30%, N 36.84%, O 42.08%
Line Formula: H2NCONHOH
Literature References: Ribonuleotide reductase inhibitor; blocks DNA synthesis and repair. Induces fetal hemoglobin production in patients with sickle cell anemia. Prepn: W. F. C. Dressler, R. Stein, Ann. 150, 242 (1869). Alternate route: P. J. Graham, US 2705727 (1955 to Du Pont). Symposium on mechanism of action and clinical experience in cancer: Semin. Oncol. 19, Suppl. 9, 1-116 (1992). Clinical trials in sickle cell crises in adults: S. Charache et al., N. Engl. J. Med. 332, 1317 (1995); in children: T. R. Kinney et al., Blood 94, 1550 (1999). Review of clinical pharmacokinetics: P. R. Gwilt, W. G. Tracewell, Clin. Pharmacokinet. 34, 347-358 (1998); of pharmacology and potential therapeutic indications: P. Navarra, P. Preziosi, Crit. Rev. Oncol. Hematol. 29, 249-255 (1999). Clinical trial in essential thrombocythemia: C. N. Harrison et al., N. Engl. J. Med. 353, 33 (2005).
Properties: Needles from alc, mp 133-136°. Freely sol in water, hot alcohol.
Melting point: mp 133-136°
Therap-Cat: Antineoplastic; in treatment of sickle cell anemia.
Keywords: Antineoplastic.